QQQ   304.59 (-0.52%)
AAPL   152.50 (-1.29%)
MSFT   256.90 (-0.56%)
META   187.55 (+0.55%)
GOOGL   103.19 (-1.52%)
AMZN   102.64 (-0.73%)
TSLA   194.48 (+2.37%)
NVDA   212.88 (+0.89%)
NIO   10.88 (-2.77%)
BABA   105.46 (-0.82%)
AMD   83.77 (-2.69%)
T   19.61 (-1.11%)
F   12.98 (-1.89%)
MU   60.33 (-3.33%)
CGC   2.94 (+0.68%)
GE   82.25 (+0.35%)
DIS   109.67 (-0.94%)
AMC   6.47 (+6.41%)
PFE   43.78 (-0.64%)
PYPL   83.10 (-2.83%)
NFLX   365.20 (-0.19%)
QQQ   304.59 (-0.52%)
AAPL   152.50 (-1.29%)
MSFT   256.90 (-0.56%)
META   187.55 (+0.55%)
GOOGL   103.19 (-1.52%)
AMZN   102.64 (-0.73%)
TSLA   194.48 (+2.37%)
NVDA   212.88 (+0.89%)
NIO   10.88 (-2.77%)
BABA   105.46 (-0.82%)
AMD   83.77 (-2.69%)
T   19.61 (-1.11%)
F   12.98 (-1.89%)
MU   60.33 (-3.33%)
CGC   2.94 (+0.68%)
GE   82.25 (+0.35%)
DIS   109.67 (-0.94%)
AMC   6.47 (+6.41%)
PFE   43.78 (-0.64%)
PYPL   83.10 (-2.83%)
NFLX   365.20 (-0.19%)
QQQ   304.59 (-0.52%)
AAPL   152.50 (-1.29%)
MSFT   256.90 (-0.56%)
META   187.55 (+0.55%)
GOOGL   103.19 (-1.52%)
AMZN   102.64 (-0.73%)
TSLA   194.48 (+2.37%)
NVDA   212.88 (+0.89%)
NIO   10.88 (-2.77%)
BABA   105.46 (-0.82%)
AMD   83.77 (-2.69%)
T   19.61 (-1.11%)
F   12.98 (-1.89%)
MU   60.33 (-3.33%)
CGC   2.94 (+0.68%)
GE   82.25 (+0.35%)
DIS   109.67 (-0.94%)
AMC   6.47 (+6.41%)
PFE   43.78 (-0.64%)
PYPL   83.10 (-2.83%)
NFLX   365.20 (-0.19%)
QQQ   304.59 (-0.52%)
AAPL   152.50 (-1.29%)
MSFT   256.90 (-0.56%)
META   187.55 (+0.55%)
GOOGL   103.19 (-1.52%)
AMZN   102.64 (-0.73%)
TSLA   194.48 (+2.37%)
NVDA   212.88 (+0.89%)
NIO   10.88 (-2.77%)
BABA   105.46 (-0.82%)
AMD   83.77 (-2.69%)
T   19.61 (-1.11%)
F   12.98 (-1.89%)
MU   60.33 (-3.33%)
CGC   2.94 (+0.68%)
GE   82.25 (+0.35%)
DIS   109.67 (-0.94%)
AMC   6.47 (+6.41%)
PFE   43.78 (-0.64%)
PYPL   83.10 (-2.83%)
NFLX   365.20 (-0.19%)
NASDAQ:SPPI

Spectrum Pharmaceuticals - SPPI Stock Forecast, Price & News

$0.81
+0.00 (+0.46%)
(As of 02/6/2023 12:52 PM ET)
Add
Compare
Today's Range
$0.80
▼
$0.83
50-Day Range
$0.32
▼
$0.85
52-Week Range
$0.32
▼
$1.57
Volume
790,775 shs
Average Volume
1.83 million shs
Market Capitalization
$153.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.44

Spectrum Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
202.6% Upside
$2.44 Price Target
Short Interest
Healthy
2.73% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.75
Upright™ Environmental Score
News Sentiment
0.17mentions of Spectrum Pharmaceuticals in the last 14 days
Based on 32 Articles This Week
Insider Trading
Selling Shares
$60,678 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.45) to ($0.21) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.47 out of 5 stars

Medical Sector

144th out of 1,025 stocks

Pharmaceutical Preparations Industry

60th out of 498 stocks

See Top Rated MarketRank™ Stocks Here
SPPI stock logo

About Spectrum Pharmaceuticals (NASDAQ:SPPI) Stock

Spectrum Pharmaceuticals, Inc. is a biotechnology company, which engages in the acquisition, development and commercialization of a pipeline of novel and targeted oncology therapies. Its product pipeline includes: Eflapegrastim, Poziotinib, and IGN002. The company was founded in December 1987 and is headquartered in Henderson, NV.

Receive SPPI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spectrum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SPPI Stock News Headlines

February 6, 2023 | americanbankingnews.com
Spectrum Pharmaceuticals (NASDAQ:SPPI) Given New $0.75 Price Target at Cantor Fitzgerald
February 4, 2023 | americanbankingnews.com
JMP Securities Reiterates "Market Outperform" Rating for Spectrum Pharmaceuticals (NASDAQ:SPPI)
February 6, 2023 | Wall Street Watch Dogs (Ad)
The #1 Energy Stock to Buy
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
February 3, 2023 | tmcnet.com
Final Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds
February 3, 2023 | wsj.com
DEADLINE TODAY: The Schall Law Firm Encourages Investors in Spectrum Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
February 3, 2023 | americanbankingnews.com
Spectrum Pharmaceuticals, Inc. Expected to Post FY2022 Earnings of ($0.42) Per Share (NASDAQ:SPPI)
February 3, 2023 | americanbankingnews.com
Spectrum Pharmaceuticals (NASDAQ:SPPI) Given Buy Rating at HC Wainwright
February 2, 2023 | wsj.com
DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Spectrum Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
February 6, 2023 | Investing Trends (Ad)
New "Vertical" Technology Solves Solar Power's Major Flaw
Even conservationists hate conventional solar farms. That's because they take up too much land and can degrade the environment. And let's face it, land is expensive...Fortunately, new groundbreaking tower technology solves solar's #1 drawback. These unique vertical structures not only take up to 90% less land space, but also generate extra electric power.
February 2, 2023 | americanbankingnews.com
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Insider Keith M. Mcgahan Sells 26,138 Shares of Stock
February 2, 2023 | americanbankingnews.com
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) CEO Thomas J. Riga Sells 69,389 Shares
February 1, 2023 | benzinga.com
FRIDAY DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Spectrum Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
January 31, 2023 | wsj.com
FRIDAY DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Spectrum Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
January 30, 2023 | wsj.com
Berger Montague PC Files a Securities Fraud Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) With Expanded Class Period
January 30, 2023 | benzinga.com
FRIDAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in Spectrum Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
January 27, 2023 | benzinga.com
7-DAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in Spectrum Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
January 26, 2023 | finance.yahoo.com
Spectrum Pharmaceuticals Announces New Employment Inducement Grant for Commercial Staff
January 25, 2023 | benzinga.com
CLASS ACTION UPDATE for SPPI, NBEVQ and IBM: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
January 25, 2023 | wsj.com
Spectrum Shareholder Notice
January 18, 2023 | benzinga.com
CLASS ACTION UPDATE for GNRC, SPPI and AVYA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
January 17, 2023 | benzinga.com
CLASS ACTION UPDATE for CURV, SPPI and FXLV: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
January 4, 2023 | finance.yahoo.com
Spectrum Pharmaceuticals Announces Management Changes
December 27, 2022 | benzinga.com
CLASS ACTION UPDATE for SPPI, VERU and SGLY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
December 20, 2022 | wsj.com
Kaplan Fox Reminds Investors with Losses in Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) of Upcoming Lead Plaintiff Deadline
December 20, 2022 | wsj.com
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Spectrum Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
December 16, 2022 | benzinga.com
SPPI LAWSUIT ALERT: Levi & Korsinsky Notifies Spectrum Pharmaceuticals, Inc. Investors Of a Class Action Lawsuit and Upcoming Deadline
December 16, 2022 | benzinga.com
CLASS ACTION UPDATE for GPS, SPPI and NEO: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
See More Headlines
Receive SPPI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spectrum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SPPI Company Calendar

Last Earnings
11/10/2022
Today
2/06/2023
Next Earnings (Estimated)
3/16/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:SPPI
CUSIP
84763A10
CIK
831547
Web
www.sppirx.com
Phone
(702) 835-6300
Fax
702-260-7405
Employees
163
Year Founded
2002

Price Target and Rating

Average Stock Price Forecast
$2.44
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$0.75
Forecasted Upside/Downside
+199.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.64)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-158,630,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-246.66%
Return on Assets
-103.55%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.28
Quick Ratio
2.09

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.29 per share
Price / Book
2.81

Miscellaneous

Outstanding Shares
188,160,000
Free Float
183,084,000
Market Cap
$153.11 million
Optionable
Optionable
Beta
2.27

Social Links


Key Executives

  • Thomas J. RigaThomas J. Riga
    President, Chief Executive Officer & Director
  • Nora E. Brennan
    Chief Financial Officer, Director & Executive VP
  • Shanta P. Chawla
    Vice President-Clinical Development
  • Keith M. McGahanKeith M. McGahan
    Secretary, Chief Legal Officer & Executive VP
  • Michael A. Grabow
    Senior VP-Corporate Strategy & Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













SPPI Stock - Frequently Asked Questions

Should I buy or sell Spectrum Pharmaceuticals stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Spectrum Pharmaceuticals in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SPPI shares.
View SPPI analyst ratings or view top-rated stocks.

What is Spectrum Pharmaceuticals' stock price forecast for 2023?

4 analysts have issued 12 month price targets for Spectrum Pharmaceuticals' shares. Their SPPI share price forecasts range from $0.75 to $4.00. On average, they anticipate the company's share price to reach $2.44 in the next year. This suggests a possible upside of 202.6% from the stock's current price.
View analysts price targets for SPPI or view top-rated stocks among Wall Street analysts.

How have SPPI shares performed in 2023?

Spectrum Pharmaceuticals' stock was trading at $0.3685 at the beginning of 2023. Since then, SPPI shares have increased by 118.6% and is now trading at $0.8055.
View the best growth stocks for 2023 here.

When is Spectrum Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 16th 2023.
View our SPPI earnings forecast.

How were Spectrum Pharmaceuticals' earnings last quarter?

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) announced its earnings results on Thursday, November, 10th. The biotechnology company reported ($0.12) earnings per share for the quarter, topping analysts' consensus estimates of ($0.15) by $0.03.

What guidance has Spectrum Pharmaceuticals issued on next quarter's earnings?

Spectrum Pharmaceuticals updated its fourth quarter 2022 earnings guidance on Tuesday, January, 31st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $10.00 million-$10.00 million, compared to the consensus revenue estimate of $3.82 million.

What is Joseph Turgeon's approval rating as Spectrum Pharmaceuticals' CEO?

2 employees have rated Spectrum Pharmaceuticals Chief Executive Officer Joseph Turgeon on Glassdoor.com. Joseph Turgeon has an approval rating of 47% among the company's employees. This puts Joseph Turgeon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Spectrum Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Spectrum Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Verastem (VSTM), Exelixis (EXEL), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Advanced Micro Devices (AMD), OPKO Health (OPK), Bausch Health Companies (BHC), Sorrento Therapeutics (SRNE) and Zynerba Pharmaceuticals (ZYNE).

What is Spectrum Pharmaceuticals' stock symbol?

Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI."

Who are Spectrum Pharmaceuticals' major shareholders?

Spectrum Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Sargent Investment Group LLC (0.25%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Francois Lebel, Jeff L Vacirca, Joseph W Turgeon, Keith M Mcgahan, Kurt A Gustafson, Nora Brennan, Seth H Z Fischer, Thomas J Riga and William Ashton.
View institutional ownership trends.

How do I buy shares of Spectrum Pharmaceuticals?

Shares of SPPI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Spectrum Pharmaceuticals' stock price today?

One share of SPPI stock can currently be purchased for approximately $0.81.

How much money does Spectrum Pharmaceuticals make?

Spectrum Pharmaceuticals (NASDAQ:SPPI) has a market capitalization of $151.56 million. The biotechnology company earns $-158,630,000.00 in net income (profit) each year or ($0.64) on an earnings per share basis.

How many employees does Spectrum Pharmaceuticals have?

The company employs 163 workers across the globe.

How can I contact Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals' mailing address is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. The official website for the company is www.sppirx.com. The biotechnology company can be reached via phone at (702) 835-6300, via email at ir@sppirx.com, or via fax at 702-260-7405.

This page (NASDAQ:SPPI) was last updated on 2/6/2023 by MarketBeat.com Staff